ROCKVILLE, Md., May 21, 2018 /PRNewswire/ -- To support quality improvement (QI) projects in breast cancer, the Associationof Community Cancer Centers (ACCC) has joined with Pfizer Independent Grants for Learning and Change (IGLC) to issue a Request for Proposals (RFP) with the intent of funding QI initiatives that fully integrate BRCA testing into patient care plans in
"Effective processes for the timely integration of molecular biomarker and genetic testing is increasingly recognized as a component of quality breast cancer care," said ACCC President Tom Gallo, MS, MDA. "Through this grant program, ACCC member programs and practices are offered an important opportunity to expand understanding and explore approaches for advancing care in this area."
BRCA mutational status can add a valuable perspective when determining optimal treatment strategies and engaging breast cancer patients in shared decision-making. However, in a recent ACCC survey of community oncology practitioners, more than 80 percent of respondents reported that fewer than half of their patients with early or metastatic breast cancer have ever had germline BRCA mutation testing. The survey revealed both patient- and provider-related barriers to BRCA testing, including institutional barriers. Access the survey summary on the ACCC website at accc-cancer.org/BRCA-testing.
"We are pleased to partner with ACCC on this grant program designed to tackle access challenges to BRCA testing, which will hopefully result in breast cancer patients having more information about their diagnoses and enable them to make more educated decisions about their care," said Julia Perkins Smith, MD, Vice President, North America Medical, Pfizer Oncology. "This is another example of Pfizer Oncology's commitment to collaborate with the oncology community to address the needs of patients affected by different types of breast cancer."
This grant program provides the opportunity for oncology programs to conduct quality improvement initiatives that address barriers experienced in their local care settings.
The opportunity to submit a proposal in response to the RFP is only available to ACCC-member cancer programs and practices. Grant requests should describe concepts and ideas for design and implementation of systems or programs that will close clinical practice gaps related to BRCA testing in breast cancer patients through establishment of education and support mechanisms for community providers.
The RFP process has two stages. Stage 1 is submission of a three-page letter of intent (LOI). If the LOI is selected, the applicant will be invited to submit a full proposal. Deadline for LOI submission is June 26, 2018.
For more information and to view the RFP, visit accc-cancer.org/BRCA-testing.
About the Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. More than 24,000 cancer care professionals from over 2,100 hospitals and practices nationwide are affiliated with ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. For more information, visit ACCC's website at www.accc-cancer.org. Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz.
Contact:Lori Gardner, Senior DirectorCommunications & Marketing301.984.9496 ext. 226
View original content:http://www.prnewswire.com/news-releases/association-of-community-cancer-centers-and-pfizer-offer-grant-opportunities-focused-on-improving-quality-of-breast-cancer-care-through-evidence-based-brca-genetic-testing-300652032.html
SOURCE Association of Community Cancer Centers
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All